EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier for C−2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers

Joanna Pilch, Agnieszka Potęga, Patrycja Kowalik, Agata Kowalczyk, Piotr Bujak, Artur Kasprzak, Ewa Paluszkiewicz, Anna Maria Nowicka

Pharmacological Reports · 2024-08 · 76 (4) · 823-837

DOI: 10.1007/s43440-024-00606-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Reports, online erschienen am 18.06.2024. Verfasst von Joanna Pilch und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry, Gdańsk University of Technology, Narutowicza 11/12 Str., Gdańsk, 80-233, Poland. joanna.pilch@pg.edu.pl. Hauptthemen laut MEDLINE: beta-Cyclodextrins, Folic Acid, Prostatic Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Traditional small-molecule chemotherapeutics usually do not distinguish tumors from healthy tissues. However, nanotechnology creates nanocarriers that selectively deliver drugs to their site of action. This work is the next step in the development of the quantum dot− β −cyclodextrin−folic acid (QD− β −CD−FA) platform for targeted and selected delivery of C−2028 unsymmetrical bisacridine in cancer therapy.

Methods

Herein, we report an initial biological evaluation (using flow cytometry and light microscopy) as well as cell migration analysis of QD− β −CD(C−2028)−FA nanoconjugate and its components in the selected human lung and prostate cancer cells, as well as against their respective normal cells.

Results

C−2028 compound induced apoptosis, which was much stronger in cancer cells compared to normal cells. Conjugation of C−2028 with QD green increased cellular senescence, while the introduction of FA to the conjugate significantly decreased this process. C−2028 nanoencapsulation also reduced cell migration. Importantly, QD green and QD green − β −CD−FA themselves did not induce any toxic responses in studied cells.

Conclusions

In conclusion, the results demonstrate the high potential of a novel folic acid-targeted receptor quantum dot− β −cyclodextrin carrier (QD green − β −CD−FA) for drug delivery in cancer treatment. Nanoplatforms increased the amount of delivered compounds and demonstrated high suitability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-CyclodextrinsFolic AcidProstatic NeoplasmsLung NeoplasmsQuantum DotsApoptosisDrug CarriersHumansMaleCell MovementAntineoplastic AgentsAcridinesCell Line, TumorDrug Delivery Systems

Stichwörter der Autor:innen

Biological responseDrug delivery nanosystemFolic acidTargeted cancer therapyUnsymmetrical bisacridine

Substanzen

beta-CyclodextrinsFolic AcidDrug CarriersAntineoplastic AgentsAcridines

Autor:innen und Institutionen

  • Faculty of Chemistry, Gdańsk University of Technology, Narutowicza 11/12 Str., Gdańsk, 80-233, Poland. joanna.pilch@pg.edu.pl.
  • Faculty of Chemistry, Gdańsk University of Technology, Narutowicza 11/12 Str., Gdańsk, 80-233, Poland.
  • Institute of Physical Chemistry, Polish Academy of Science, Warsaw, Poland.
  • Faculty of Chemistry, University of Warsaw, Warsaw, Poland.
  • Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Pilch, J., Potęga, A., Kowalik, P., Kowalczyk, A., Bujak, P., Kasprzak, A., Paluszkiewicz, E., & Nowicka, A. M. (2024). In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier for C−2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers. Pharmacological Reports, 76(4), 823-837. https://doi.org/10.1007/s43440-024-00606-4

Vancouver

Pilch J, Potęga A, Kowalik P, Kowalczyk A, Bujak P, Kasprzak A, et al. In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier for C−2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers. Pharmacological Reports. 2024;76(4):823-837. doi:10.1007/s43440-024-00606-4

BibTeX
@article{Pilch2024,
  author = {Pilch, Joanna and Potęga, Agnieszka and Kowalik, Patrycja and Kowalczyk, Agata and Bujak, Piotr and Kasprzak, Artur and Paluszkiewicz, Ewa and Nowicka, Anna Maria},
  title = {In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier for C−2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers},
  journal = {Pharmacological Reports},
  year = {2024},
  volume = {76},
  number = {4},
  pages = {823--837},
  doi = {10.1007/s43440-024-00606-4}
}
Kostenlos starten →